Stocks
Aligos Therapeutics, Inc.ALGS
NASDAQHealthcareBiotechnology$4.86
Price as of · delayed, not real-time
Aligos Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for chronic hepatitis B and other viral infections. Its pipeline includes small molecule drug candidates targeting viral replication and host factors, with lead programs in Phase 2 trials. Investors track the stock for its potential in the hepatitis B treatment market and its clinical data readouts.
52W Range: $3.98-$13.69
Congressional Interest in Aligos Therapeutics, Inc. (ALGS)
No congressional trades have been disclosed for Aligos Therapeutics, Inc. (ALGS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading ALGS?
No congressional trades found for this stock.